Perspective Therapeutics Q3 net loss $15.1M ($0.21/share); cash $267.8M funds into mid-2026

Perspective Therapeutics, Inc.

2024-Q3 EPS reported -$0.62

Net loss from continuing and discontinued ops $15.1M vs $10.4M YoY; basic loss per share $0.21.
Cash, equivalents and short-term investments $267.8M (Sep 30, 2024) vs $9.2M at Dec 31, 2023.
R&D expense surged 114% to $12.0M; G&A expense up 56% to $7.0M; no product revenue.
Phase 1/2a trials advancing: VMT-α-NET and VMT01; combo cohort with nivolumab open.
Manufacturing capacity expanded: second cGMP facility in Somerset, NJ and three new buildings purchased.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.